AMAG Pharmaceuticals Inc., of Lexington, Mass., reported total first quarter revenue of $13.4 million, of which $10.9 million were net product revenues from Feraheme (ferumoxytol) Injection for intravenous use to treat iron deficiency anemia in adult chronic kidney disease patients, compared to total revenue of $13.3 million for the same period in 2010.